ANI Pharmaceuticals Beat Masks a Cortrophin Guideline Cut Worth Watching

ANI Pharmaceuticals reported second-quarter earnings of $2.21 on a non-GAAP basis, beating consensus by $0.17, and revenue of $266 million, ahead of the $260 million estimate. The stock rose 3.4% on the print. On the surface, another beat, another green candle. But if you look past the headline numbers, the Cortrophin Gel guidance adjustment tells a story the headline doesn't capture.

Cortrophin Gel — ANI's rare-disease specialty product and the engine behind its transformation from a generics player into a high-margin biopharma — grew 43.5% year-over-year in Q2, bringing in $117.1 million. That's a strong quarter. But management cut full-year Cortrophin revenue guidance from $540 million to $575 million down to $520 million to $540 million, while leaving total company revenue and non-GAAP EPS guidance unchanged at $1,080–$1,140 million and $9.19–$9.69, respectively.

That's the tension. Cortrophin accounted for roughly 44% of total revenue in Q2, making it the single biggest growth driver. Cutting its guidance while holding the rest of the outlook steady implies management expects either meaningful offset from elsewhere in the portfolio — the ILUVIEN retinal implant, generics pipeline, or brand royalties — or that the earlier Cortrophin outlook simply priced in too aggressive a trajectory. Given that first-half Cortrophin came in at roughly $192 million ($75.1 million in Q1 plus $117.1 million in Q2), the new midpoint of $530 million requires H2 to deliver about $338 million, or roughly 2.9 times the Q2 run rate over two quarters. That's aggressive. The cut to $520–$540 million may be a course correction rather than a warning, but it signals the growth curve isn't as certain as the Q2 print alone might suggest.

What about valuation? ANIP trades at roughly 40 times forward earnings, with trailing P/E near 20.5x and a TTM P/S of 2.0x. Revenue growth is 37% year-over-year, putting the rough P/E-to-growth ratio around 1.1x. That's fair, not cheap. This isn't the kind of valuation disconnect — forward multiples converging with the broader market while growth runs three to five times faster — that typically triggers a contrarian buy alert. At 40x forward earnings, the market has baked in a continued execution story, including the Cortrophin expansion. That means the margin of safety isn't there at current levels.

Free cash flow, however, is the strongest part of the operating picture. ANI generated $182.8 million in trailing-twelve-month free cash flow, representing a 19.8% FCF margin — up 277% year-over-year. Operating cash flow was $208.6 million. That kind of cash conversion is unusual for a specialty pharma company and gives the business real optionality. The board already acted on it, authorizing a $100 million share repurchase program through May 2029. Buybacks on this scale for a $1.88 billion market cap company signal management confidence, even if the balance sheet carries elevated leverage — $859.7 million in total debt against $562.3 million in equity, a debt-to-equity ratio of 109%.

The gross margin pressure is another data point worth noting. Both GAAP and non-GAAP gross margins declined in Q2, driven by the higher mix of royalty-bearing Cortrophin sales (where ANI doesn't retain all the margin) and the non-recurrence of prior-year Prucalopride revenues. SG&A expenses jumped 20.2% on a non-GAAP basis as the company ramps the rare-disease sales force expansion. The CEO called it the "largest Rare Disease sales force expansion in our history," targeting an estimated 285,000-patient addressable market for acute gouty arthritis flares. Over 95% of the new representatives generated multiple new patient cases in their first stint. Early metrics are positive, but the expansion hasn't fully flowed through to the guidance yet — or perhaps that's exactly why guidance was trimmed.

Price action doesn't flash urgency either. The stock sits near both its 50-day ($81.0) and 200-day ($81.0) moving averages, having drifted down from a 52-week high of $99.50 to around $82.63. The RSI is at 56, flat in neutral territory. The MACD is slightly negative. This isn't a beaten-down setup where selling exhaustion has created an asymmetric entry. It's a stock that has consolidated through the spring and summer, popped modestly on an earnings beat, and is now sitting at a technical crossroads.

AInvest's aggregate signal labels the stock a Buy, with a fundamental rating of 7.98 out of 10 and a composite analysis score of 1.04. That consensus lean is understandable given the growth profile, but consensus doesn't create margin of safety — valuation and price action do.

The core takeaway: ANI is a well-executing company with an exceptional free cash flow trajectory and a rare-disease franchise that's still growing fast. But the Cortrophin guidance cut introduces enough uncertainty that I don't see the valuation at 40x forward earnings as offering the asymmetric risk/reward a contrarian entry requires. The stock isn't being punished by the market, and it doesn't need to be for this to be a "wait" call. If ANIP gets sold off on the guidance trim — or if the gout expansion ramp validates the earlier growth trajectory and pulls the stock back toward its highs — the picture changes. For now, I'd keep it on the watchlist rather than chase. The better entry is likely below $80, or after the guidance question resolves with concrete H2 Cortrophin data.

I would reassess to the upside if the stock weakens toward the low-$70s with the fundamentals intact, which would create the valuation gap this setup currently lacks. I would reassess to the downside if H2 Cortrophin revenue fails to clear $150 million per quarter, suggesting the guidance cut was understated rather than conservative.